Cornerstone Therapeutics Inc. (CRTX) - NASDAQ
CRTX is defunct.
  • Nov. 7, 2013, 12:41 PM
    • Cornerstone Therapeutics, Inc. (CRTX): Q3 EPS of $0.46.
    • Revenue of $53.69M beats by $11.69M. (PR)
    | Nov. 7, 2013, 12:41 PM
  • Aug. 6, 2013, 5:17 PM
    • Cornerstone Therapeutics (CRTX): Q2 EPS of $0.33.
    • Revenue of $40.4M beats by $4.61M. (PR)
    | Aug. 6, 2013, 5:17 PM
  • May 9, 2013, 9:50 AM
    Cornerstone Therapeutics (CRTX): Q1 EPS of $0.24 beats by $0.11. Revenue of $38M beats by $2.57M. (PR)
    | May 9, 2013, 9:50 AM
  • Mar. 14, 2013, 7:22 AM
    Cornerstone Therapeutics (CRTX): Q4 EPS of -$0.26 misses by $0.36. Revenue of $34.9M misses by $1.1M. (PR)
    | Mar. 14, 2013, 7:22 AM
  • Nov. 8, 2012, 7:58 AM
    Cornerstone Therapeutics (CRTX): Q3 EPS of $0.19 misses by $0.13. Revenue of $37.5M (+49% Y/Y) beats by $5.5M. (PR)
    | Nov. 8, 2012, 7:58 AM
Company Description
Cornerstone Therapeutics, Inc., is a specialty pharmaceutical company which commercializes products for the hospital and adjacent specialty markets.
Sector: Healthcare
Industry: Biotechnology
Country: United States